Enveric Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 17.29 million compared to USD 18.47 million a year ago. Basic loss per share from continuing operations was USD 8.09 compared to USD 13 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.895 USD | -0.56% | +1.64% | -31.15% |
Mar. 26 | Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 19 | Sector Update: Health Care Stocks Rise Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.15% | 6.53M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ENVB Stock
- News Enveric Biosciences, Inc.
- Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023